Clinical and preclinical evidence suggests that mecamylamine, a nicotinic receptor antagonist, may have anxiolytic properties. The purpose of this study was to further investigate the anxiolytic properties of mecamylamine in rats as measured by the Elevated Plus Maze and the Social Interaction models of anxiety and to determine if manipulation of the testing environment (either brightly lit or dimly lit conditions) influenced the results. Results indicated that mecamylamine had significant anxiolytic effects in both the Elevated Plus Maze and Social Interaction Tests and that these effects were dependent on dose administered and the level of anxiety produced under different testing conditions. If confirmed by further clinical research, nicotinic receptor antagonists like mecamylamine may represent a novel class of anxiolytics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1037//1064-1297.10.1.18 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of Sertraline and Vortioxetine on Stress-Induced Brain Injury in Rats: Biochemical and Histopathological Evaluations.
Clin Neuropharmacol
January 2025
Medical Biochemistry, Erzincan Binali Yıldırım University Faculty of Medicine, Erzincan, Turkey.
Objectives: Our aim was to evaluate the comparative effects of sertraline and vortioxetine against stress-induced brain injury in rats.
Methods: The rats were assigned to a nonstress group (NSG), stress-treated control (StC), sertraline + stress (SSt), and vortioxetine + stress (VSt) groups. Sertraline and vortioxetine (10 mg/kg) were given orally by gavage to the SSt and VSt groups.
Safety concerns associated with the use of benzodiazepines during MRI.
Nursing
December 2024
Tammy McClung is a nursing instructor of the RN to BSN program at the College of Brockport, State University of New York, in Brockport, N.Y. She also holds a per diem clinical position in urgent care at the University of Rochester.
Magnetic resonance imaging (MRI) is a powerful diagnostic tool that uses strong magnetic fields and radio waves to create detailed images of the body's internal structures. This article examines the challenges associated with MRI, particularly focusing on patient anxiety and claustrophobic reactions that can lead to aborted scans. It discusses the use of anxiolytics, especially benzodiazepines, to manage these issues, while highlighting the potential risks of respiratory depression and other adverse outcomes in select patient populations.
View Article and Find Full Text PDFCBD and the 5-HT1A receptor: A medicinal and pharmacological review.
Biochem Pharmacol
January 2025
Department of Biomedical Sciences, College of Medicine, University of Houton, Houston, TX, 77204, USA. Electronic address:
Cannabidiol (CBD), a phytocannabinoid, has emerged as a promising candidate for addressing a wide array of symptoms. It has the ability to bind multiple proteins and receptors, including 5-HT1AR, transient receptor potential vanilloid 1 (TRPV1), and cannabinoid receptors. However, CBD's pharmacodynamic interaction with 5-HT1AR and its medicinal outcomes are still debated.
View Article and Find Full Text PDFSigma-1 Receptor as a Novel Therapeutic Target in Diabetic Kidney Disease.
Int J Mol Sci
December 2024
MTA-SE Lendület "Momentum" Diabetes Research Group, 1083 Budapest, Hungary.
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease. Current treatments for DKD do not halt renal injury progression, highlighting an urgent need for therapies targeting key disease mechanisms. Our previous studies demonstrated that activating the Sigma-1 receptor (S1R) with fluvoxamine (FLU) protects against acute kidney injury by inhibiting inflammation and ameliorating the effect of hypoxia.
View Article and Find Full Text PDFDexmedetomidine Improves Learning Functions in Male Rats Modeling Cognitive Impairment by Modulating the BDNF/TrkB/CREB Signaling Pathway.
Life (Basel)
December 2024
Department of Pharmacology, Ministry of Health, Derince Education and Research Hospital, 41100 Kocaeli, Türkiye.
Dexmedetomidine (DEX) is a selective alpha-2 adrenergic receptor agonist with sedative and anxiolytic properties. Increasing evidence reports that DEX has a neuroprotective effect. In this study, we investigated the potential effects of DEX on learning and memory functions in rats with experimental cognitive impairment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!